A citation-based method for searching scientific literature

Satoshi Yoda, Ibiayi Dagogo-Jack, Aaron N Hata. Pharmacol Ther 2019
Times Cited: 30







List of co-cited articles
91 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
23

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
16

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
13

Lung cancer: current therapies and new targeted treatments.
Fred R Hirsch, Giorgio V Scagliotti, James L Mulshine, Regina Kwon, Walter J Curran, Yi-Long Wu, Luis Paz-Ares. Lancet 2017
13

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen,[...]. Science 2007
10

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.
Cai-Hong Yun, Kristen E Mengwasser, Angela V Toms, Michele S Woo, Heidi Greulich, Kwok-Kin Wong, Matthew Meyerson, Michael J Eck. Proc Natl Acad Sci U S A 2008
10

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Justin F Gainor, Alice T Shaw. Oncologist 2013
215
10

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
10

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
10


EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
10


STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
552
10

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, C A Shu, R Umeton, J Montecalvo, A Ni, R Chen, J Dienstag, C Mrad, I Bergagnini,[...]. Ann Oncol 2018
115
10


Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.
Jeff W Kwak, Jennifer Laskowski, Howard Y Li, Maria V McSharry, Trisha R Sippel, Bonnie L Bullock, Amber M Johnson, Joanna M Poczobutt, Alexander J Neuwelt, Stephen P Malkoski,[...]. Cancer Res 2018
48
6

Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis.
Mary C M Weiser-Evans, Xue-Qing Wang, Jay Amin, Vicki Van Putten, Rashmi Choudhary, Robert A Winn, Robert Scheinman, Peter Simpson, Mark W Geraci, Raphael A Nemenoff. Cancer Res 2009
44
6

Tumor-associated macrophages: from mechanisms to therapy.
Roy Noy, Jeffrey W Pollard. Immunity 2014
6

Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis.
Howard Li, Amber L Sorenson, Joanna Poczobutt, Jay Amin, Teresa Joyal, Timothy Sullivan, Joseph T Crossno, Mary C M Weiser-Evans, Raphael A Nemenoff. PLoS One 2011
50
6

The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Howard Y Li, Maria McSharry, Bonnie Bullock, Teresa T Nguyen, Jeff Kwak, Joanna M Poczobutt, Trisha R Sippel, Lynn E Heasley, Mary C Weiser-Evans, Eric T Clambey,[...]. Cancer Immunol Res 2017
53
6

Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment.
Joanna M Poczobutt, Teresa T Nguyen, Dwight Hanson, Howard Li, Trisha R Sippel, Mary C M Weiser-Evans, Miguel Gijon, Robert C Murphy, Raphael A Nemenoff. J Immunol 2016
44
6

Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cells of the microenvironment.
Joanna M Poczobutt, Miguel Gijon, Jay Amin, Dwight Hanson, Howard Li, Deandra Walker, Mary Weiser-Evans, Xian Lu, Robert C Murphy, Raphael A Nemenoff. PLoS One 2013
34
6


MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
James Bean, Cameron Brennan, Jin-Yuan Shih, Gregory Riely, Agnes Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, Janos Szoke, Stephen Broderick,[...]. Proc Natl Acad Sci U S A 2007
6

K-Ras protein as a drug target.
Frank McCormick. J Mol Med (Berl) 2016
59
6

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
6

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Khyati N Shah, Roma Bhatt, Julia Rotow, Julia Rohrberg, Victor Olivas, Victoria E Wang, Golzar Hemmati, Maria M Martins, Ashley Maynard, Jonathan Kuhn,[...]. Nat Med 2019
97
6


Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
A Vaishnavi, M Capelletti, A T Le, S Kako, M Butaney, D Ercan, S Mahale, K D Davies, D L Aisner, A B Pilling,[...]. Nat Med 2013
369
6


Cancer statistics in China, 2015.
Wanqing Chen, Rongshou Zheng, Peter D Baade, Siwei Zhang, Hongmei Zeng, Freddie Bray, Ahmedin Jemal, Xue Qin Yu, Jie He. CA Cancer J Clin 2016
6

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Maria E Arcila, Jamie E Chaft, Khedoudja Nafa, Sinchita Roy-Chowdhuri, Christopher Lau, Michael Zaidinski, Paul K Paik, Maureen F Zakowski, Mark G Kris, Marc Ladanyi. Clin Cancer Res 2012
264
6

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.
Chiara Tomasello, Cinzia Baldessari, Martina Napolitano, Giulia Orsi, Giulia Grizzi, Federica Bertolini, Fausto Barbieri, Stefano Cascinu. Crit Rev Oncol Hematol 2018
29
6

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Snjezana Dogan, Ronglai Shen, Daphne C Ang, Melissa L Johnson, Sandra P D'Angelo, Paul K Paik, Edyta B Brzostowski, Gregory J Riely, Mark G Kris, Maureen F Zakowski,[...]. Clin Cancer Res 2012
319
6

ERBB receptors and cancer: the complexity of targeted inhibitors.
Nancy E Hynes, Heidi A Lane. Nat Rev Cancer 2005
6

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
Kang-Yi Su, Hsuan-Yu Chen, Ker-Chau Li, Min-Liang Kuo, James Chih-Hsin Yang, Wing-Kai Chan, Bing-Ching Ho, Gee-Chen Chang, Jin-Yuan Shih, Sung-Liang Yu,[...]. J Clin Oncol 2012
408
6

Oncogene addiction.
I Bernard Weinstein, Andrew Joe. Cancer Res 2008
624
6

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Yi-Long Wu, Caicun Zhou, Cheng-Ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, Mei Hou, Jian Hua Shi, Kye Young Lee,[...]. Lancet Oncol 2014
6

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Matthew R Janes, Jingchuan Zhang, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Xin Guo, Yuching Chen, Anjali Babbar, Sarah J Firdaus, Levan Darjania,[...]. Cell 2018
408
6

Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Xibin Zhuang, Chao Zhao, Jiayu Li, Chunxia Su, Xiaoxia Chen, Shengxiang Ren, Xuefei Li, Caicun Zhou. Cancer Med 2019
24
8

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Susumu Kobayashi, Titus J Boggon, Tajhal Dayaram, Pasi A Jänne, Olivier Kocher, Matthew Meyerson, Bruce E Johnson, Michael J Eck, Daniel G Tenen, Balázs Halmos. N Engl J Med 2005
6

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, Paul Baas, Fabrice Barlesi, Trever G Bivona, Roy S Herbst, Tony S Mok, Nir Peled, Robert Pirker,[...]. J Thorac Oncol 2018
271
6

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B Turke, Panos Fidias, Kristin Bergethon, Alice T Shaw, Scott Gettinger, Arjola K Cosper,[...]. Sci Transl Med 2011
6


Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
6

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi,[...]. J Clin Oncol 2018
129
6

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
6

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Helena A Yu, Maria E Arcila, Natasha Rekhtman, Camelia S Sima, Maureen F Zakowski, William Pao, Mark G Kris, Vincent A Miller, Marc Ladanyi, Gregory J Riely. Clin Cancer Res 2013
6


Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Hongbin Ji, Zhenxiong Wang, Samanthi A Perera, Danan Li, Mei-Chih Liang, Sara Zaghlul, Kate McNamara, Liang Chen, Mitchell Albert, Yanping Sun,[...]. Cancer Res 2007
132
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.